Circassia To Present At EAACI Annual Meeting, Barcelona, Spain, 6-10 June 2015
Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty biopharmaceutical company focused on allergy, today announces that clinical and non-clinical data relating to the Company's novel immunotherapy candidates targeting house dust mite, grass and cat allergies will be presented at the 2015 European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting held in Barcelona, Spain on 6-10 June.
Sunday, 7 June 2015
Oral Abstract Session
13:30 - 15:00 Rooms 127-128
Session Title: Efficacy and clinical outcomes
Comparison of the treatment effect of house dust mite synthetic 13:40 - 13:53
peptide immuno-regulatory epitopes in the environmental exposure chamber
and field setting two years after a short course of treatment
Presenter: Roderick Hafner (United Kingdom)
Monday, 8 June 2015
Oral Abstract Session
10:45 - 12:15 Room 212
Session Title: Innovations in immunotherapy
Persistent treatment effect with grass synthetic peptide immuno-regulatory 11:21 - 11:34
epitopes (Grass-SPIRE) on grass allergy symptoms in the environmental
exposure unit after a third season of natural exposure
Presenter: Anne Ellis (Canada)
Tuesday, 9 June 2015
Late Breaking Poster Session
12:00 - 13:30 Poster exhibition
Session Title: Immunotherapy
Whole blood immune transcriptome profiling reveals systemic pathways 12:00 - 13:30
associated with the mechanism of action of cat-synthetic peptide
Presenter: Daniel Gliddon (United Kingdom)
Notes to editors
Circassia is a specialty biopharmaceutical company focused on the development and commercialization of a range of allergy immunotherapy product candidates. Established in 2006, the Company has used its proprietary ToleroMune® technology to develop a new class of therapies, Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs), which have the potential to revolutionize allergy treatment.
The Company's portfolio of SPIREs is designed to treat a broad range of seasonal and perennial allergies. The most advanced, Cat-SPIRE, targets cat allergy and is currently in phase III development. Three other product candidates, targeting house dust mite, ragweed and grass allergies, have completed clinical proof-of-concept phase IIb studies.
Further information is available at: http://www.circassia.com.
For further information, please contact:
Steve Harris, Chief Executive Officer
Julien Cotta, Chief Financial Officer
Rob Budge, Corporate Communications
Ben Atwell / Simon Conway / Mo Noonan
Help employers find you! Check out all the jobs and post your resume.